Top

Published in:

Open Access 01-12-2005 | Research

Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation

Authors: Christophe Rosty, Marie-Hélène Aubriot, David Cappellen, Jérôme Bourdin, Isabelle Cartier, Jean Paul Thiery, Xavier Sastre-Garau, François Radvanyi

Published in: Molecular Cancer | Issue 1/2005

Abstract

Background

We have previously reported activating mutations of the gene coding for the fibroblast growth factor receptor 3 (FGFR3) in invasive cervical carcinoma. To further analyze the role of FGFR3 in cervical tumor progression, we extended our study to screen a total of 75 invasive tumors and 80 cervical intraepithelial neoplasias (40 low-grade and 40 high-grade lesions).

Results

Using single strand conformation polymorphism (SSCP) followed by DNA sequencing, we found FGFR3 mutation (S249C in all cases) in 5% of invasive cervical carcinomas and no mutation in intraepithelial lesions. These results suggest that, unlike in bladder carcinoma, FGFR3 mutation does not or rarely occur in non invasive lesions. Compared to patients with wildtype FGFR3 tumor, patients with S249C FGFR3 mutated tumors were older (mean age 64 vs. 49.4 years, P = 0.02), and were more likely to be associated with a non-16/18 HPV type in their tumor. Gene expression analysis demonstrated that FGFR3 mutated tumors were associated with higher FGFR3b mRNA expression levels compared to wildtype FGFR3 tumors. Supervised analysis of Affymetrix expression data identified a significant number of genes specifically differentially expressed in tumors with respect to FGFR3 mutation status.

Conclusion

This study suggest that tumors with FGFR3 mutation appear to have distinctive clinical and biological characteristics that may help in defining a population of patients for FGFR3 mutation screening.

Available only for authorised users

Ferlay F, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No.5. 2001, Lyon, IARCPress

zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002, 2: 342-350. 10.1038/nrc798CrossRefPubMed

Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL: Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003, 95: 1336-1343.CrossRefPubMed

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-527. 10.1056/NEJMoa021641CrossRefPubMed

Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999, 23: 18-20.PubMed

Robertson SC, Tynan J, Donoghue DJ: RTK mutations and human syndromes: when good receptors turn bad. Trends Genet. 2000, 16: 368- 10.1016/S0168-9525(00)02077-1CrossRefPubMed

Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997, 16: 260-264. 10.1038/ng0797-260PubMedCentralCrossRefPubMed

Van Rhijn BW, Van Tilborg AA, Lurkin I, Bonaventure J, De Vries A, Thiery JP, Van Der Kwast TH, Zwarthoff EC, Radvanyi F: Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 2002, 10: 819-824. 10.1038/sj.ejhg.5200883CrossRefPubMed

Yee CJ, Lin O, Boyd J: Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma. J Natl Cancer Inst. 2000, 92: 1848-1849. 10.1093/jnci/92.22.1848CrossRefPubMed

10.

Wu R, Connolly D, Ngelangel C, Bosch FX, Munoz N, Cho KR: Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene. 2000, 19: 5543-5546. 10.1038/sj.onc.1203934CrossRefPubMed

11.

Dai H, Holm R, Kristensen GB, Abeler VM, Borresen-Dale AL, Helland A: Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas. Anal Cell Pathol. 2001, 23: 45-49.CrossRefPubMed

12.

Sibley K, Stern P, Knowles MA: Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene. 2001, 20: 4416-4418. 10.1038/sj.onc.1204543CrossRefPubMed

13.

Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003, 88: 63-73. 10.1038/sj.bjc.6600688PubMedCentralCrossRefPubMed

14.

Tavormina PL, Rimoin DL, Cohn DH, Zhu YZ, Shiang R, Wasmuth JJ: Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet. 1995, 4: 2175-2177.CrossRefPubMed

15.

Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Cremoux P, de La Rochefordiere A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F, Domany E, Sastre-Garau X: Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Submitted

16.

Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP, Radvanyi F: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001, 158: 1955-1959.PubMedCentralCrossRefPubMed

17.

Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y: The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer. 2001, 92: 2555-2561. 10.1002/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-MCrossRefPubMed

18.

Kong M, Wang CS, Donoghue DJ: Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activation. J Biol Chem. 2002, 277: 15962-15970. 10.1074/jbc.M102777200CrossRefPubMed

19.

Lievens PM, Liboi E: The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J Biol Chem. 2003, 278: 17344-17349. 10.1074/jbc.M212710200CrossRefPubMed

20.

Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordiere A, Clough K, Favre M, Pouillart P, Sastre-Garau X: Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol. 1998, 16: 2613-2619.PubMed

21.

Webster MK, Donoghue DJ: FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 1997, 13: 178-182. 10.1016/S0168-9525(97)01131-1CrossRefPubMed

22.

Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donoghue DJ, Thompson LM, Francomano CA: A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet. 1999, 64: 722-731. 10.1086/302275PubMedCentralCrossRefPubMed

23.

Diez de Medina SG, Chopin D, El Marjou A, Delouvee A, LaRochelle WJ, Hoznek A, Abbou C, Aaronson SA, Thiery JP, Radvanyi F: Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene. 1997, 14: 323-330. 10.1038/sj.onc.1200830CrossRefPubMed

24.

Murgue B, Tsunekawa S, Rosenberg I, deBeaumont M, Podolsky DK: Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res. 1994, 54: 5206-5211.PubMed

25.

Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001, 98: 5116-5121. 10.1073/pnas.091062498PubMedCentralCrossRefPubMed

Title: Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation
Authors: Christophe Rosty
Marie-Hélène Aubriot
David Cappellen
Jérôme Bourdin
Isabelle Cartier
Jean Paul Thiery
Xavier Sastre-Garau
François Radvanyi
Publication date: 01-12-2005
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2005
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-4-15

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2005

Gene expression profiling of tumours derived from rasV12/E1A-transformed mouse embryonic fibroblasts to identify genes required for tumour development

Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression

Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion

Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization

Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome

p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer